EMERYVILLE, Calif.–(BUSINESS WIRE)– Eureka Therapeutics, Inc., a clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing novel T
September 13, 2017 08:00 AM Eastern Daylight Time EMERYVILLE, Calif.–(BUSINESS WIRE)– Eureka Therapeutics, Inc., a clinical stage biotechnology company focused on developing novel T-cell immunotherapies for
POTENTIAL TO ACCELERATE APPLICATION OF CAR-T THERAPY TO OTHER SOLID TUMORS June 07, 2017 08:00 AM Eastern Daylight Time EMERYVILLE, Calif. & DUARTE, Calif. -Eureka
April 20, 2017 08:00 AM Eastern Daylight Time EMERYVILLE, Calif. -Eureka Therapeutics, Inc., a biotechnology company focused on developing novel T-cell immunotherapies for the treatment
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.